US EditionPublished • loading... • Updated
SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
- SCG Cell Therapy Pte Ltd announced the presentation of first-in-human clinical data for SCG142 in patients with HPV-associated carcinomas at the ESMO Congress 2025 in Berlin, Germany, on October 18, 2025.
- The trial showed tumor shrinkage in all seven treated patients, leading to a 100% disease control rate.
- Prof. Dr. Yang Li stated that these findings support further evaluation in larger patient cohorts for patients with HPV-associated cancers.
- Dr. Susanne Wilde expressed satisfaction that the preclinical profile of SCG142 has translated into clinical activity.
Insights by Ground AI
29 Articles
29 Articles
Rutland Herald+27 Reposted by 27 other sources
SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigator-initiated Phase I…
Coverage Details
Total News Sources29
Leaning Left8Leaning Right3Center6Last UpdatedBias Distribution47% Left
Bias Distribution
- 47% of the sources lean Left
47% Left
L 47%
C 35%
R 18%
Factuality
To view factuality data please Upgrade to Premium
